CORT

Business Context and Reporting Period

Company: Corcept Therapeutics Incorporated (CORT)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Corcept is a commercial-stage biopharmaceutical company focused on treating severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol. Key products include Korlym (and its authorized generic) for hypercortisolism and Lifyorli (relacorilant), which received FDA approval in March 2026 for platinum-resistant ovarian cancer and began commercial distribution in April 2026.

Key Financial Metrics

Margins: Gross margin was approximately 98.3% (Cost of sales was $2.9M vs Revenue of $164.9M). Operating margin turned negative at -30.1% compared to 2.2% in the prior year.

Material Changes vs. Prior Period

• Revenue Growth: Net product revenue increased 4.9% year-over-year, driven by a 12.4% increase in sales volume. This was partially offset by a 6.7% decrease in average selling price due to higher volume of the authorized generic version of Korlym.
• Expense Surge: Total operating expenses increased $60.7 million (39.5%).
  • Selling, General & Administrative (SG&A): Rose from $90.7M to $145.4M, primarily due to increased sales and marketing activities to support the commercialization of Lifyorli and Hypercortisolism products.
  • Research & Development (R&D): Increased from $60.7M to $66.3M, driven by advancement of development programs and employee compensation.
• Profitability: The company reported a net loss of $31.8M in Q1 2026, a reversal from a net income of $20.5M in Q1 2025, primarily due to the significant increase in operating expenses.
• Cash Flow: Operating cash flow shifted from positive ($4.8M) to negative ($16.8M) due to the net loss and working capital changes.

Guidance, Outlook, Risks, and Unusual Items

• Commercial Outlook: Management expects SG&A and R&D expenses to remain higher in 2026 to support commercialization efforts. The company anticipates funding operations for the next 12 months without raising additional capital.
• Regulatory Developments:
  • Lifyorli: FDA approved for ovarian cancer (March 2026); commercial launch began April 2026. An MAA was submitted to the EMA in October 2025.
  • Relacorilant (Hypercortisolism): Received a Complete Response Letter (CRL) from the FDA in December 2025 declining approval, citing a need for additional efficacy evidence. The company is working with the FDA on the path to approval.
• Legal Proceedings:
  • Securities Class Action: Filed in February 2026 alleging misleading statements regarding the relacorilant NDA.
  • Patent Litigation: The Federal Circuit affirmed a ruling in February 2026 that Teva's generic Korlym does not infringe Corcept's patents. Corcept filed a petition for rehearing en banc in April 2026.
  • Antitrust Litigation: Ongoing suits by Teva and insurance companies alleging antitrust violations regarding specialty pharmacy arrangements.
• Risk Factors: Significant risks include the impact of the Inflation Reduction Act (IRA) on Medicare pricing, potential restrictions on mifepristone (active ingredient in Korlym) due to political/legal debates, and the uncertainty of generic competition.

Investor Verification Checklist

• Relacorilant Path to Approval: Verify the specific additional data or trials required by the FDA following the December 2025 CRL for the hypercortisolism indication.
• Patent Litigation Status: Monitor the outcome of the petition for rehearing en banc regarding the Teva patent infringement case, which impacts Korlym's exclusivity.
• Lifyorli Commercialization: Track early sales data and market adoption rates for Lifyorli following its April 2026 launch.
• Specialty Pharmacy Transition: Confirm the stability and performance of the new specialty pharmacy vendor (Curant) following the termination of the agreement with Optime Care.
• IRA Impact: Assess the specific financial impact of the Inflation Reduction Act's inflation rebate provisions on 2026 revenue projections.